Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 18/20 | 0.93 |
| ▸ | RAF1 | P04049 | 1/20 | 0.93 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb590885 SCHEMBL15442151 | 1.00 | BRAF (0.93) | BRAFRAF1ALOX5 | |
| Sb590885 SCHEMBL12518520 | 1.00 | BRAF (0.93) | BRAFRAF1ALOX5 | |
| Sb590885 SCHEMBL15667975 | 1.00 | BRAF (0.93) | BRAFRAF1ALOX5 | |
| Sb590885 SCHEMBL150830 | 0.97 | BRAF (1.00) | BRAFRAF1 | |
| Sb590885 SCHEMBL131578 | 0.97 | BRAF (1.00) | BRAFRAF1 | |
| Sb590885 SCHEMBL14754822 | 0.97 | BRAF (1.00) | BRAFRAF1 | |
| SCHEMBL5406959 | 0.92 | BRAF (0.92) | BRAFRAF1ALOX5 | |
| SCHEMBL5406954 | 0.92 | BRAF (0.92) | BRAFRAF1ALOX5 | |
| SCHEMBL5470151 | 0.87 | BRAF (0.83) | BRAFRAF1 | |
| SCHEMBL15449798 | 0.87 | BRAF (0.82) | BRAFRAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 857 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735598-A2 | NRAS GENE KNOCKOUT FOR TREATMENT OF CANCER | Christiana Care Gene Editing Institute, Inc. (US) | 2026-05-06 | — | — | EP | claimed |
| EP-4728051-A1 | STANDARDISING PLURIPOTENT STEM CELLS | United Kingdom Research and Innovation (GB) | 2026-04-22 | — | — | EP | claimed |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BIOMED VALLEY DISCOVERIES, INC. (US) | 2026-03-24 | — | — | US | claimed |
| US-12522872-B2 | Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-13 | — | — | US | claimed |
| US-20250340848-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | PEKING UNIVERSITY (CN) | 2025-11-06 | — | — | US | claimed |
| WO-2025217050-A1 | METHODS OF PREPARING INDUCED PLURIPOTENT STEM CELLS FROM MESENCHYMAL STEM CELLS AND METHODS OF USING THE SAME | THE MEDICAL COLLEGE OF WISCONSIN, INC. (US) | 2025-10-16 | — | — | WO | claimed |
| EP-4602148-A1 | METHODS FOR CHEMICAL REPROGRAMMING AND PLURIPOTENT STEM CELLS | Peking University (CN) | 2025-08-20 | — | — | EP | claimed |
| US-12385008-B2 | Method for producing retinal tissue | Sumitomo Pharma Co., Ltd. (JP) | 2025-08-12 | — | — | US | claimed |
| EP-4587026-A1 | COMBINATIONS | Recurium IP Holdings, LLC (US) | 2025-07-23 | — | — | EP | claimed |
| US-20250205240-A1 | COMBINATIONS | RECURIUM IP HOLDINGS, LLC | 2025-06-26 | — | — | US | claimed |
| US-11439648-B2 | Use of topical BRAF inhibitor compositions for treatment of radiation dermatitis | LUTRIS PHARMA LTD. (IL) | 2022-09-13 | — | — | US | claimed |
| US-20220177842-A1 | METHOD FOR LONG-TERM EX VIVO MAINTENANCE OR EXPANSION OF HUMAN ERYTHROBLAST, HUMAN MEGAKARYOCYTE-ERYTHROID PROGENITOR, OR HUMAN COMMON MYELOID PROGENITOR CELL AND APPLICATION THEREOF | OCGENE THERAPEUTICS CORPORATION | 2022-06-09 | — | — | US | claimed |
| WO-2022120153-A1 | METHOD FOR LONG-TERM EX VIVO MAINTENANCE OR EXPANSION OF HUMAN ERYTHROBLAST, MEGAKARYOCYTE-ERYTHROID PROGENITOR, OR COMMON MYELOID PROGENITOR CELL | OCGENE THERAPEUTICS CORPORATION (US) | 2022-06-09 | — | — | WO | claimed |
| EP-3775288-B1 | MIRNAS FOR TREATMENT AND IN VITRO DIAGNOSIS OF DRUG RESISTANT TUMORS | ST FISIOTERAPICI OSPITALIERI (IT) | 2022-06-01 | — | — | EP | claimed |
| EP-4003332-A1 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2022-06-01 | — | — | EP | claimed |
| US-20220162711-A1 | IDENTIFICATION OF DRUGS TARGETING NON-GENETIC DRUG TOLERANCE PROGRAMS IN CANCER | ETH ZURICH (CH) | 2022-05-26 | — | — | US | claimed |
| US-20220142979-A1 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2022-05-12 | — | — | US | claimed |
| EP-3987006-A1 | CELL CULTURE | Agency For Science, Technology And Research (SG) | 2022-04-27 | — | — | EP | claimed |
| WO-2022073469-A1 | COMPOUNDS AND METHODS OF TREATING CANCERS | CULLGEN (SHANGHAI) , INC. (CN) | 2022-04-14 | — | — | WO | claimed |
| EP-3559276-B1 | IDENTIFICATION OF DRUGS TARGETING NON-GENETIC DRUG TOLERANCE PROGRAMS IN CANCER | ETH ZUERICH (CH) | 2022-03-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220142979-A1 | PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND USE THEREOF FOR PREVENTING AND/OR TREATING DISEASE | MDM2, TP53, BRCA1 | BRAF 707/4885RAF1 670/4885ALOX5 1895/4885 |
| US-12582635-B2 | Compositions and methods for treating cancer with atypical BRAF mutations | BRAF, SRMS, MAPK3 | BRAF 1/4885RAF1 50/4885ALOX5 2614/4885 |
| US-11439648-B2 | Use of topical BRAF inhibitor compositions for treatment of radiation dermatitis | BRAF, NRAS, RAF1 | BRAF 1/4885RAF1 3/4885ALOX5 943/4885 |
| US-20250205240-A1 | COMBINATIONS | MCL1, TP53, BRCA1 | BRAF 321/4885RAF1 1437/4885ALOX5 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.